Synaffix Entered into a License Agreement with Amgen to Develop Antibody-Drug Conjugates to Treat Cancer
Shots:
- Under the terms of the agreement, Synaffix is eligible for up to $2B including spanning signature, program nomination & milestones along with tiered royalties
- Amgen receives exclusive, worldwide rights to develop & commercialize Ab-drug conjugates by using its Ab conjugation technology platforms incl. GlycoConnect, HydraSpace & select toxSYN linker payloads for one ADC program against cancer
- Additionally, Amgen holds an exclusive option to license for additional four programs & will be responsible for the R&D, manufacturing, & commercialization of the ADCs
Ref: PRNewswire | Image: Amgen
Related News:- Merck Signs a Research Collaboration and Commercial License Agreement with Mersana for Novel Antibody-Drug Conjugates
Click here to read the full press release